CytRx’s Seeking Destruction Of Cancer Cells (NASDAQ:CYTR)

CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company’s drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a study for the treatment of acute promyelocytic leukemia (APL). CytRx is also developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.

CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells. CytRx Corporation currently has two clinical-stage molecular chaperone drug candidates and has discovered a series of additional compounds that may provide a pipeline for additional drug candidates. The drug candidates made by CytRx are believed to function through regulation of normal cellular protein repair pathway activated by molecular chaperons that help in reduction of misfolded proteins. CytRx has already submitted Food and Drug Administration with their revised protocol for its clinical trial with arimoclomol for the treatment of ALS.

The paper’s written by Stuart K. Calderwood, Ph.D., of Beth Israel Deaconess Medical Center, Harvard Medical School, reviewed 40 clinical and animal studies and found that molecular chaperones play a vital role in the deterrence of protein damage during the aging process and that chaperone expression is required for cell longevity and which opens new blockbuster opportunities for our molecular chaperone technology beyond the large neurodegenerative disease, stroke recovery and neuropathy markets. Several pharmaceutical companies are currently evaluating potential partnerships aimed at advancing development of this technology in the future.